Stock of the Day

October 25, 2024

Janux Therapeutics (JANX)

$18.66
+$0.44 (+2.4%)
Market Cap: $1.14B

About Janux Therapeutics

Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma. Its development pipeline also consists of discovery stage products. The company has strategic research collaboration agreement with Merck Sharp & Dohme Corp. to develop TRACTr product candidates. Janux Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California.

Today's Trend

Janux Therapeutics, Inc. (NASDAQ: JANX) shares have recently decreased as investors weigh supportive analyst endorsements and improved quarterly results against continued losses and mixed earnings forecasts.

  • Bank of America maintained its Buy rating on Janux Therapeutics, signaling continued confidence in the company’s outlook and potentially limiting downside pressure. Bank of America Securities Sticks to Its Buy Rating for Janux Therapeutics
  • Janux was highlighted among analysts’ top healthcare stock picks, reinforcing positive sentiment around its biotechnology platform and development pipeline. Analysts’ Top Healthcare Picks
  • A recent earnings update indicated narrower net losses and an improved earnings profile, which helped support the stock after the report. Janux Therapeutics Is Up After Reporting Narrower Net Losses
  • HC Wainwright raised its FY2026 EPS forecast to a loss of $1.69 from $1.89 and increased several 2027 quarterly and full-year estimates, suggesting some near-term improvement in expected losses. However, Janux is still projected to remain unprofitable, with a FY2027 loss estimate of $2.36 per share.
  • HC Wainwright lowered its FY2028 EPS estimate to a loss of $2.72 from $2.51 and its FY2029 estimate to a loss of $1.11 from $1.00. The firm’s more cautious long-term outlook may be weighing on sentiment. HC Wainwright Issues Pessimistic Estimate for JANX Earnings
  • The company’s latest quarterly results missed analyst expectations for both EPS and revenue, underscoring continued execution and funding risks typical of a clinical-stage biotechnology company.
← Previous Stock of the DayNext Stock of the Day →